v3.26.1
Business Segment Information
 6 Months Ended
Jun. 27, 2026
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
Business Segment Information
The company’s financial performance is reported in four segments. During 2026, there have been no changes to the company’s basis of segmentation or in the basis of measurement of segment income. Other segment items included in the below tables consist of stock-based compensation and other incentive compensation expenses, allocations of corporate expenses and certain overhead expenses, as well as elimination of intersegment and intrasegment profits. Prior period segment expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.
2026
Three months ended June 27, 2026
(In millions)Life Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesTotal
Revenues
Revenues from external customers$2,355 $1,799 $1,188 $6,652 $11,994 
Intersegment revenues460 47 17 41 565 
2,815 1,847 1,205 6,693 12,559 
Elimination of intersegment revenues
(565)
Consolidated revenues
$11,994 
Segment Income
Cost of revenues1,080 925 699 5,150 
Selling, general, and administrative expenses500 315 177 677 
Research and development expenses140 140 45 27 
Other segment items54 43 (50)(97)
Segment income
1,041 424 334 936 2,735 
Unallocated amounts
Cost of revenues adjustments
(28)
Selling, general and administrative expenses adjustments
(36)
Restructuring and other costs
(98)
Amortization of acquisition-related intangible assets
(485)
Interest income207 
Interest expense(401)
Other income/(expense)
31 
Consolidated income before income taxes$1,924 
(In millions)Unallocated amountsLife Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesConsolidated
Segment assets$98,003 $3,508 $3,187 $1,323 $7,152 $113,174 
Purchases of property, plant and equipment90 59 17 24 260 450 
Depreciation of property, plant and equipment— 69 27 20 216 331 
2025
Three months ended June 28, 2025
(In millions)Life Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesTotal
Revenues
Revenues from external customers$2,115 $1,669 $1,118 $5,953 $10,855 
Intersegment revenues385 58 16 42 501 
2,499 1,728 1,134 5,995 11,356 
Elimination of intersegment revenues
(501)
Consolidated revenues$10,855 
Segment Income
Cost of revenues925 902 640 4,667 
Selling, general, and administrative expenses467 317 183 595 
Research and development expenses135 145 47 14 
Other segment items54 39 (42)(106)
Segment income
919 325 306 825 2,375 
Unallocated amounts
Cost of revenues adjustments
(10)
Selling, general and administrative expenses adjustments
(20)
Restructuring and other costs
(82)
Amortization of acquisition-related intangible assets
(429)
Interest income297 
Interest expense(404)
Other income/(expense)
(19)
Consolidated income before income taxes$1,709 
(In millions)Unallocated amountsLife Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesConsolidated
Segment assets$87,013 $3,142 $3,070 $1,295 $6,711 $101,230 
Purchases of property, plant and equipment25 25 13 25 206 294 
Depreciation of property, plant and equipment— 56 26 23 152 256 
2026
Six months ended June 27, 2026
(In millions)Life Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesTotal
Revenues
Revenues from external customers$4,574 $3,466 $2,312 $12,647 $22,999 
Intersegment revenues877 96 34 82 1,089 
5,450 3,563 2,346 12,729 24,088 
Elimination of intersegment revenues
(1,089)
Consolidated revenues
$22,999 
Segment Income
Cost of revenues2,084 1,801 1,356 9,907 
Selling, general, and administrative expenses996 628 354 1,274 
Research and development expenses271 278 89 41 
Other segment items105 76 (99)(208)
Segment income
1,994 779 646 1,714 5,133 
Unallocated amounts
Cost of revenues adjustments
(42)
Selling, general and administrative expenses adjustments
(79)
Restructuring and other costs
(147)
Amortization of acquisition-related intangible assets
(915)
Interest income440 
Interest expense(755)
Other income/(expense)
22 
Consolidated income before income taxes$3,658 
(In millions)Unallocated amountsLife Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesConsolidated
Segment assets$98,003 $3,508 $3,187 $1,323 $7,152 $113,174 
Purchases of property, plant and equipment117 79 52 59 518 826 
Depreciation of property, plant and equipment— 139 53 44 402 638 
2025
Six months ended June 28, 2025
(In millions)Life Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesTotal
Revenues
Revenues from external customers$4,069 $3,346 $2,248 $11,556 $21,219 
Intersegment revenues771 99 34 79 983 
4,840 3,446 2,282 11,635 22,202 
Elimination of intersegment revenues
(983)
Consolidated revenues
$21,219 
Segment Income
Cost of revenues1,781 1,737 1,319 9,077 
Selling, general, and administrative expenses935 631 354 1,183 
Research and development expenses274 282 92 27 
Other segment items98 71 (93)(209)
Segment income
1,753 724 610 1,557 4,644 
Unallocated amounts
Cost of revenues adjustments
(21)
Selling, general and administrative expenses adjustments
(34)
Restructuring and other costs
(180)
Amortization of acquisition-related intangible assets
(859)
Interest income501 
Interest expense(707)
Other income/(expense)
(16)
Consolidated income before income taxes$3,329 
(In millions)Unallocated amountsLife Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsLaboratory Products and Biopharma ServicesConsolidated
Segment assets$87,013 $3,142 $3,070 $1,295 $6,711 $101,230 
Purchases of property, plant and equipment61 69 57 58 412 656 
Depreciation of property, plant and equipment— 114 50 44 324 532